Board of Directors
Malcolm J McComas BEc LLB Independent Chairman (Appointed as Chairman on 1 May 2012)
Gary J Phillips BPharm MBA Chief Executive Officer (Appointed on 12 March 2013)
William L Delaat AM BSc Non-Executive Director
Simon HW Buckingham BVSc (Hons), PhD Non-Executive Director (Appointed on 25 July 2012)
Dr Kathleen M Metters B.S. Ph.D. Non-Executive Director (Appointed on 7 June 2017)
David M McGarvey BA CA CPA Company Secretary
Senior Management Team
Gary J Phillips, BPharm MBA Chief Executive Officer (Appointed on 12 March 2013)
David M McGarvey BA CA CPA Chief Financial Officer
Brett Charlton MBBS PhD Medical Director
Wolfgang G Jarolimek BSc PhD Head of Drug Discovery
Kristen Morgan BSc PGDipBusAdmin, MMedSc Alliance Management
Board of Directors
Our Board of Directors bring a broad range of qualifications and experience to the Company including:
 |
Malcolm J McComas BEc LLB Independent Chairman (Appointed as Chairman on 1 May 2012) |
Malcolm has been a member of the Board of Directors since July 2003 and Chairman of the Board since 2012. He is a company director, former investment banker and commercial lawyer. Malcolm is the principal of McComas Capital and was previously a director of investment banking and funds management group Grant Samuel.
Malcolm is a former Managing Director of investment banking at County NatWest and its successor organisation Salomon Smith Barney (now Citigroup). He has held various executive roles with Morgan Grenfell (now Deutsche Bank) in Melbourne, Sydney and London.
Malcolm has worked with many high growth companies across various industry sectors and has experience in equity and debt finance, acquisitions and divestments and privatisations. He has led more than 50 initial public offerings and significant secondary offerings for companies, institutions and governments. Malcolm is Chairman of Fitzroy River Corporation Limited, a director of Saunders International Limited and the Australasian Leukaemia and Lymphoma Group and a senior advisor to CW Downer & Co. He was the former President of Finsia (the Financial Services Institute of Australia) and previously a director of Consolidated Minerals Limited, Ocean Capital Limited and BC Iron Limited.
Malcolm is chairman of the Pharmaxis Remuneration and Nomination Committee and a member of the Audit Committee.
 |
Gary J Phillips B Pharm MBA Chief Executive Officer (Appointed on 12 March 2013) |
Gary joined the Company in 2003 and was appointed Chief Executive Officer and became a member of the Board of Directors in March 2013. He previously held the positions of Commercial Director and Chief Operating Officer. Gary has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.
From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (merged to form Novartis in 1996) where he led the successful launch of a portfolio of new products. After a period of 3 years as an area manager for Novartis responsible for 9 countries in Asia Pacific in 2001 he joined Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division, successfully launching leading oncology and ophthalmology products. Gary holds a BPharm in Pharmacy with honors from Nottingham University in the UK and an MBA from Henley Management College.
 |
William L Delaat AM BSc Non-Executive Director |
Will has been a member of the Board of Directors since June 2008. He has more than 35 years' experience in the global pharmaceutical industry, most recently as the Managing Director of the Australian subsidiary of Merck & Co, a position he held from 1997 until his retirement in 2008.
During his career Will has held executive positions in both Europe and Australia for Merck and AstraZeneca. He has a broad depth of experienced in pharmaceutical sales and marketing and has been responsible for numerous international product launches.
Will was Chairman of the pharmaceutical peak body Medicines Australia, and the Pharmaceuticals Industry Council from 2008-2012. He is also Chairman of EnGeneIC Ltd, an unlisted Australian biotech company, and a director of the George Institute for Global Health Board.
Will holds a Bachelor of Science, Physiology & Chemistry, from the University of London.
Will is Chair of the Pharmaxis Audit Committee and a member of the Remuneration and Nomination Committee.
 |
Simon HW Buckingham BVSc (Hons), PhD Non-Executive Director (Appointed on 25 July 2012) |
Simon has been a member of the Board of Directors since July 2012. He has over 25 years' experience in the global pharmaceutical industry across a range of functions and a variety of therapeutic areas. Now based in Sydney, Simon is currently a senior global advisor to Actelion, one of the world's leading biopharmaceutical companies, and is a director of Actelion Australia. He was President, Global Corporate and Business Development at Actelion from 2005-2011, a position which spanned licensing, M&A, alliance management and corporate strategic planning. Simon served as President, North America and Asia-Pacific at Actelion from 2000-2005, with responsibility for all commercial operations in the region. He was the founding President of Actelion Pharmaceuticals US. From 1998-2000 he worked in sales and marketing for Parke-Davis (now part of Pfizer) in the US and prior to that served in roles in sales, marketing and development at Roche, both in Switzerland and Australia, for 9 years.
Simon is currently a non-executive director of European based Vaxxilon and also of the Can Too Foundation, a non-profit organisation raising funds for cancer research. He holds a Bachelor of Veterinary Science degree from the University of Sydney, a PhD from the University of Melbourne, a Graduate Management Qualification from the AGSM, University of NSW and is a Graduate of the Australian Institute of Company Directors. Simon is a member of the Pharmaxis Audit Committee and the Remuneration & Nomination Committee.
 |
Dr Kathleen M Metters B.S. Ph.D. Non-Executive Director (Appointed on 7 June 2017) |
Dr Kathleen Metters joined the Board of Directors in June 2017 bringing more than 25 years of experience in the discovery and development of novel therapies for treatment of serious diseases. She was formerly the Senior Vice President and Head of Worldwide Basic Research for Merck & Co. with oversight of all the company’s global research projects. In a subsequent role at Merck &Co. she led work on External Discovery and Preclinical Sciences.
Kathleen was President and CEO of biopharmaceutical company Lycera Corp and is currently an independent consultant and senior advisor for Bridge Medicines.
Kathleen graduated with a B.S. in biochemistry from the University of Manchester Institute for Science and Technology, and a Ph.D. from Imperial College of Science and Technology in London.
 |
David M McGarvey BA CA CPA Company Secretary and Chief Financial Officer |
David has been Chief Financial Officer and Company Secretary since December 2002. He is a seasoned CFO with thirty years' experience building and funding Australian based companies from inception to globally successful enterprises.
From 1998 to 2002 David served as Chief Financial Officer of the Filtration and Separations Division of US Filter. From 1985 to 1997 he served as Chief Financial Officer of Memtec Limited. While at Memtec and US Filter, David oversaw the US listing of the company on the Nasdaq Global Market and the New York Stock Exchange and managed numerous international merger and acquisition transactions. From 1975 to 1985, he held various positions at PriceWaterhouseCoopers.
David holds a BA in Accounting from Macquarie University and was admitted to the Chartered Accountants Australia and New Zealand in 1981 and to the membership of CPA Australia in 1993.
Senior Management Team
The senior management team has significant combined international experiences in drug discovery and development, clinical trial design and management, regulatory and pricing approvals, intellectual property protection and management, commercialisation, pharmaceutical manufacturing, business development and capital markets.
|
Gary J Phillips B Pharm MBA Chief Executive Officer (Appointed on 12 March 2013) |
Gary joined the Company in 2003 and was appointed Chief Executive Officer and became a member of the Board of Directors in March 2013. He previously held the positions of Commercial Director and Chief Operating Officer. Gary has more than 30 years of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia.
From 1994 to 1998, he was Chief Executive Officer at Ciba Geigy in Hungary (merged to form Novartis in 1996) where he led the successful launch of a portfolio of new products. After a period of 3 years as an area manager for Novartis responsible for 9 countries in Asia Pacific in 2001 he joined Novartis Australia as Group Company Head and Chief Executive Officer of its Pharmaceutical Division, successfully launching leading oncology and ophthalmology products. Gary holds a BPharm in Pharmacy with honors from Nottingham University in the UK and an MBA from Henley Management College.
|
David M McGarvey BA CA CPA Company Secretary and Chief Financial Officer |
David has been Chief Financial Officer and Company Secretary since December 2002. He is a seasoned CFO with thirty years' experience building and funding Australian based companies from inception to globally successful enterprises.
From 1998 to 2002 David served as Chief Financial Officer of the Filtration and Separations Division of US Filter. From 1985 to 1997 he served as Chief Financial Officer of Memtec Limited. While at Memtec and US Filter, David oversaw the US listing of the company on the Nasdaq Global Market and the New York Stock Exchange and managed numerous international merger and acquisition transactions. From 1975 to 1985, he held various positions at PriceWaterhouseCoopers.
David holds a BA in Accounting from Macquarie University and was admitted to the Chartered Accountants Australia and New Zealand in 1981 and to the membership of CPA Australia in 1993.
 |
Brett Charlton MBBS PhD Medical Director |
Brett co-founded Pharmaxis in 1998 and has served continuously as the Company's Medical Director overseeing all aspects of clinical research.
Brett is the author of more than 60 scientific papers with 15 years of experience in clinical trial design and management. He was founding Medical Director of the National Health Sciences Centre and established its Clinical Trials Unit. Prior to joining Pharmaxis he held various positions with the Australian National University, Stanford University, the Baxter Centre for Medical Research, Royal Melbourne Hospital, and the Walter and Eliza Hall Institute.
Brett holds a MBBS with honors from the University of New South Wales and a PhD from the University of New South Wales.
 |
Wolfgang G Jarolimek BSc PhD Head of Drug Discovery |
Wolfgang joined Pharmaxis in September 2010 as Manager in vitro Pharmacology and was appointed Head Drug Discovery in August 2012.
He has more than 15 years' experience in pharmaceutical drug discovery and has published more than 20 peer reviewed articles. From 2002 to 2010 Wolfgang was Director of Assay Development and Compound Profiling at the GlaxoSmithKline Center of Excellence in Drug Discovery in Verona, Italy. In addition to chairing early drug discovery efforts locally he also had global responsibilities for ion channel screening and implementing safety-related screening. From 1998 to 2002 he worked at the Neuroscience Center of Merck, Sharp and Dohme in Harlow, England, as Senior Research Scientist in the electrophysiology group. Wolfgang previously spent 8 years as post-doc at the Max-Plank Institute in Munich, Germany; Baylor College of Medicine, Houston, Texas; Rammelkamp Center, Cleveland Ohio; and University of Heidelberg, Germany.
Wolfgang holds a BSc in Pharmacy and a PhD from the University of Saarbrücken, Germany. In 1997 he became Assistant Professor in Physiology at the University of Heidelberg, Germany.
 |
Kristen Morgan BSc PGDipBusAdmin, MMedSc Alliance Management |
Kristen joined Pharmaxis in August 2008 and now has responsibility for Alliance Management and Medical and Regulatory Affairs. She has 19 years' experience in the pharmaceutical industry having previously held a senior role in medical affairs at Sanofi-Aventis, and a commercial sales role at GlaxoSmithKline. Kris holds a BSc from Queensland University (major in pharmacology), a Postgraduate Diploma of Business Administration from Queensland University of Technology and a Masters of Medical Science (Drug Development) from University of New South Wales.
updated 7th June, 2017
| © Copyright 1996-2019 irasia.com Ltd. All rights reserved. |
|
DISCLAIMER: irasia.com Ltd makes no guarantee as to the accuracy or completeness of any
information provided on this website. Under no circumstances shall irasia.com Ltd be liable
for damages resulting from the use of the information provided on this website.
TRADEMARK & COPYRIGHT: All intellectual property rights subsisting in the contents of this website belong to irasia.com Ltd or have been lawfully licensed to irasia.com Ltd for use on this website. All rights under applicable laws are hereby reserved. Reproduction of this website in whole or in part without the express written permission of irasia.com Ltd is strictly prohibited. TERMS OF USE: Please read the Terms of Use governing the use of our website. |